$DNLI
Denali Therapeutics Inc. Stock $dnli

$dnli Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000171489924000086 Filed on February 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$0.00	$0.00	$330.5M
YoY Change	-100.0%	-100.0%	204.74%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$25.24M	$24.77M	$103.4M
YoY Change	-7.02%	5.33%	14.23%
% of Gross Profit
Research & Development	$107.0M	$107.8M	$423.9M
YoY Change	-16.92%	17.04%	18.16%
% of Gross Profit
Depreciation & Amortization	$2.162M	$2.177M	$16.70M
YoY Change	-78.48%	-46.79%	60.58%
% of Gross Profit
Operating Expenses	$132.3M	$132.6M	$527.2M
YoY Change	-15.2%	14.65%	17.37%
Operating Profit	-$117.7M		-$196.7M
YoY Change	-2.57%		-42.27%
Interest Expense	$15.91M	$13.13M	$51.51M
YoY Change	44.22%	97.13%	248.62%
% of Operating Profit
Other Income/Expense, Net			$51.51M
YoY Change			248.62%
Pretax Income	-$101.8M	-$119.4M	-$145.2M
YoY Change	-7.27%	21.04%	-55.46%
Income Tax		$30.00K	$30.00K
% Of Pretax Income
Net Earnings	-$101.8M	-$119.5M	-$145.2M
YoY Change	-7.27%	21.07%	-55.45%
Net Earnings / Revenue			-43.94%
Basic Earnings Per Share	-$0.68		-$1.06
Diluted Earnings Per Share	-$0.68	-$0.86	-$1.06
COMMON SHARES
Basic Shares Outstanding	139.2M shares	138.2M shares	137.4M shares
Diluted Shares Outstanding	149.4M shares		137.4M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$936.9M	$1.035B	$1.035B
YoY Change	-27.29%	-22.58%	-22.58%
Cash & Equivalents	$60.57M	$127.1M	$127.1M
Short-Term Investments	$876.3M	$907.4M	$907.4M
Other Short-Term Assets	$36.71M	$29.63M	$29.63M
YoY Change	-0.01%	-17.94%	-17.94%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$973.6M	$1.064B	$1.064B
YoY Change	-26.53%	-22.46%	-22.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$46.86M	$45.59M	$71.64M
YoY Change	11.27%	3.41%	-3.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$490.7M
YoY Change
Other Assets	$44.62M	$18.14M	$18.14M
YoY Change	218.36%	35.41%	35.41%
Total Long-Term Assets	$607.5M	$89.78M	$89.78M
YoY Change	621.67%	2.11%	2.11%
TOTAL ASSETS
Total Short-Term Assets	$973.6M	$1.064B	$1.064B
Total Long-Term Assets	$607.5M	$89.78M	$89.78M
Total Assets	$1.581B	$1.154B	$1.154B
YoY Change	12.19%	-20.98%	-20.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.86M	$9.483M	$9.483M
YoY Change	435.21%	239.89%	239.89%
Accrued Expenses	$5.986M	$68.50M	$68.50M
YoY Change	-93.39%	2.71%	2.71%
Deferred Revenue		$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$82.58M	$77.98M	$77.98M
YoY Change	-78.88%	-78.57%	-78.57%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$43.03M	$0.00	$44.98M
YoY Change	11254.62%	-100.0%	-16.53%
Total Long-Term Liabilities	$43.03M	$0.00	$44.98M
YoY Change	11254.62%	-100.0%	-16.53%
TOTAL LIABILITIES
Total Short-Term Liabilities	$82.58M	$77.98M	$77.98M
Total Long-Term Liabilities	$43.03M	$0.00	$44.98M
Total Liabilities	$125.6M	$123.0M	$123.0M
YoY Change	-71.62%	-70.57%	-70.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.218B	-$1.116B
YoY Change	12.7%	14.96%
Common Stock		$1.711M
YoY Change		1.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.455B	$1.031B	$1.031B
YoY Change
Total Liabilities & Shareholders Equity	$1.581B	$1.154B	$1.154B
YoY Change	12.19%	-20.98%	-20.98%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$101.8M	-$119.5M	-$145.2M
YoY Change	-7.27%	21.07%	-55.45%
Depreciation, Depletion And Amortization	$2.162M	$2.177M	$16.70M
YoY Change	-78.48%	-46.79%	60.58%
Cash From Operating Activities	-$113.6M	-$98.66M	-$358.0M
YoY Change	93.22%	35.77%	46.29%
INVESTING ACTIVITIES
Capital Expenditures	$2.150M	$2.235M	$12.94M
YoY Change	-22.83%	-53.91%	-27.44%
Acquisitions
YoY Change
Other Investing Activities	-$451.0M	$75.28M	$262.2M
YoY Change	401.55%	-161.35%	-312.25%
Cash From Investing Activities	-$453.2M	$73.05M	$249.3M
YoY Change	388.8%	-157.27%	-276.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$500.3M	4.705M	$17.82M
YoY Change	31089.21%	-98.43%	-94.26%
NET CHANGE
Cash From Operating Activities	-$113.6M	-98.66M	-$358.0M
Cash From Investing Activities	-$453.2M	73.05M	$249.3M
Cash From Financing Activities	$500.3M	4.705M	$17.82M
Net Change In Cash	-$66.53M	-20.90M	-$90.86M
YoY Change	-55.62%	-121.03%	20.46%
FREE CASH FLOW
Cash From Operating Activities	-$113.6M	-$98.66M	-$358.0M
Capital Expenditures	$2.150M	$2.235M	$12.94M
Free Cash Flow	-$115.8M	-$100.9M	-$370.9M
YoY Change	87.97%	30.16%	41.28%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2023Q4	us-gaap	Liabilities Liabilities	122963000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	138385498	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1711000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2144811000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	643000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1116211000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1030954000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1153917000	usd
CY2023	us-gaap	Revenues Revenues	330531000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	423876000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	103354000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	90475000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	449207000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	344412000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-340744000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4595000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	379000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	417812000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	135965918	shares
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2018617000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6886000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-970987000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1042430000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1460242000	usd
CY2021	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	4000	usd
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001714899
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38311
CY2023	dei	Entity Registrant Name EntityRegistrantName	Denali Therapeutics Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3872213
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	161 Oyster Point Blvd
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2023	dei	City Area Code CityAreaCode	650
CY2023	dei	Local Phone Number LocalPhoneNumber	866-8548
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2023	dei	Trading Symbol TradingSymbol	DNLI
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	2000000000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	139160239	shares
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	San Mateo, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	127106000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	218044000	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	907405000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1118171000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	29626000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	36104000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1064137000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1372319000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	45589000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44087000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	26048000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	30437000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	18143000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	13399000	usd
CY2023Q4	us-gaap	Assets Assets	1153917000	usd
CY2022Q4	us-gaap	Assets Assets	1460242000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9483000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2790000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4388000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	68499000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	66691000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	290053000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	479000	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	138385498	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	135965918	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1686000	usd
CY2023	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	0	usd
CY2022	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	3398000	usd
CY2022	us-gaap	Revenues Revenues	108463000	usd
CY2021	us-gaap	Revenues Revenues	48661000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-196699000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	51505000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14774000	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-145194000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-325970000	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-291156000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	30000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	21000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-575000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-290581000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.06
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.60
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.39
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.39
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	137370897	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	137370897	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	125530703	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	121524795	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1150531000	usd
CY2021	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	19348000	usd
CY2021	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	85247000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-290581000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-2254000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	962291000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	1060000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	296215000	usd
CY2022	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	14455000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	99847000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-325991000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4387000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1042430000	usd
CY2023	dnli	Stock Issued During Period Value Equity Incentive Plan StockIssuedDuringPeriodValueEquityIncentivePlan	17820000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	108399000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-145224000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	7529000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	1030954000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-145224000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-325991000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-290581000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16726000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10383000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8593000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	108102000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	99847000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	85247000	usd
CY2023	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	43952000	usd
CY2022	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	1637000	usd
CY2021	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-8748000	usd
CY2023	dnli	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	3719000	usd
CY2022	dnli	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	3351000	usd
CY2021	dnli	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	2984000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-2000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-63000	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4094000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2760000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	12865000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2431000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2274000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3705000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2648000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	10918000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4732000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-31313000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-11925000	usd
CY2023	dnli	Increase Decrease In Contract With Customer Liability Related Parties IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties	-290532000	usd
CY2022	dnli	Increase Decrease In Contract With Customer Liability Related Parties IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties	-3149000	usd
CY2021	dnli	Increase Decrease In Contract With Customer Liability Related Parties IncreaseDecreaseInContractWithCustomerLiabilityRelatedParties	-3737000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-379000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-322000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-357991000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-244716000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-211389000	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1813700000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1115040000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1422938000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12939000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17833000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8500000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2075947000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	991486000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1409812000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	249308000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-141387000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21626000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	296215000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	17820000	usd
CY2022	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	14455000	usd
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	19348000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	17820000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	310670000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19348000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-90863000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-75433000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-213667000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	219544000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	294977000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	508644000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	128681000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	219544000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	294977000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	47000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	210000	usd
CY2023	dnli	Issuance Costs Incurred But Not Yet Paid IssuanceCostsIncurredButNotYetPaid	0	usd
CY2022	dnli	Issuance Costs Incurred But Not Yet Paid IssuanceCostsIncurredButNotYetPaid	224000	usd
CY2021	dnli	Issuance Costs Incurred But Not Yet Paid IssuanceCostsIncurredButNotYetPaid	0	usd
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	553000	usd
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1464000	usd
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	593000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates, and such differences could be material to the Consolidated Balance Sheets and Consolidated Statements of Operations and Comprehensive Loss.</span></div>
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1028439000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1277240000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	906410000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	998000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	907405000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1124718000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	96000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. Substantially all of the Company’s cash and cash equivalents are deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. </span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment policy limits investments to certain types of securities issued by the U.S. government and its agencies, as well as institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and marketable securities and issuers of marketable securities to the extent recorded on the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Balance Sheets</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, 2023 and 2022, the Company had no off-balance sheet concentrations of credit risk.</span></div><div style="margin-top:10pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other clinical-stage biopharmaceutical companies, including, but not limited to, the need to obtain adequate additional funding, possible failure of current or future preclinical testing or clinical trials, its reliance on third parties to conduct its clinical trials, the need to obtain regulatory and marketing approvals for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company’s product candidates, its right to develop and commercialize its product candidates pursuant to the terms and conditions of the licenses granted to the Company, protection of proprietary technology, the ability to make milestone, royalty or other payments due under any license or collaboration agreements, and the need to secure and maintain adequate manufacturing arrangements with third parties. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate product revenue or achieve profitability. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the company is also subject to broad market risks and uncertainties resulting from recent events, such as bank failures or instability in the financial services sector, the COVID-19 pandemic, war and armed conflicts, inflation, rising interest rates, and recession risks as well as supply chain and labor shortages.</span></div>
CY2022Q4	dnli	Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk Amount ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRiskAmount	0	usd
CY2023Q4	dnli	Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk Amount ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRiskAmount	0	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	40000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1600000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1500000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	6643000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1118171000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P1Y
CY2023	us-gaap	Revenues Revenues	330531000	usd
CY2022	us-gaap	Revenues Revenues	108463000	usd
CY2021	us-gaap	Revenues Revenues	48661000	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3420000	usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	9282000	usd
CY2023Q4	dnli	Prepaid Clinical Research And Development Expense Current PrepaidClinicalResearchAndDevelopmentExpenseCurrent	10178000	usd
CY2022Q4	dnli	Prepaid Clinical Research And Development Expense Current PrepaidClinicalResearchAndDevelopmentExpenseCurrent	8895000	usd
CY2023Q4	dnli	Prepaid Manufacturing And Other Research And Development Expense Current PrepaidManufacturingAndOtherResearchAndDevelopmentExpenseCurrent	12192000	usd
CY2022Q4	dnli	Prepaid Manufacturing And Other Research And Development Expense Current PrepaidManufacturingAndOtherResearchAndDevelopmentExpenseCurrent	13834000	usd
CY2023Q4	dnli	Other Prepaid Expense And Other Assets Current OtherPrepaidExpenseAndOtherAssetsCurrent	3836000	usd
CY2022Q4	dnli	Other Prepaid Expense And Other Assets Current OtherPrepaidExpenseAndOtherAssetsCurrent	4093000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	29626000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	36104000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	91592000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	81302000	usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.39
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20500000	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18200000	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16500000	shares
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	46003000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	37215000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	45589000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	44087000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16700000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10400000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8600000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	21590000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17087000	usd
CY2023Q4	dnli	Accrued Clinical And Other Accrued Research And Development Costs AccruedClinicalAndOtherAccruedResearchAndDevelopmentCosts	19035000	usd
CY2022Q4	dnli	Accrued Clinical And Other Accrued Research And Development Costs AccruedClinicalAndOtherAccruedResearchAndDevelopmentCosts	16297000	usd
CY2023Q4	dnli	Other Accrued Manufacturing Costs OtherAccruedManufacturingCosts	15462000	usd
CY2022Q4	dnli	Other Accrued Manufacturing Costs OtherAccruedManufacturingCosts	22307000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7260000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7318000	usd
CY2023Q4	dnli	Other Accrued Costs And Other Liabilities Current OtherAccruedCostsAndOtherLiabilitiesCurrent	5152000	usd
CY2022Q4	dnli	Other Accrued Costs And Other Liabilities Current OtherAccruedCostsAndOtherLiabilitiesCurrent	3682000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	68499000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	66691000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	12400000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	12000000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	11000000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	11345000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	11189000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	10336000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y2M12D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y3M18D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.090
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	24.3
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	23.96
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	11.83
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	11417000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	11793000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	12182000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	12584000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	13001000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	4381000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	65358000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	13117000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	52241000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14673717	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.03
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M26D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	127865000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3482231	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	27.51
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	916235	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	13.01
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	749162	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	39.64
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	16490551	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.34
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y11M19D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	61982000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	15680680	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	28.72
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y2M23D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	45153000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10918798	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	25.93
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y1M20D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	45085000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	12100000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	12600000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	47900000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	17.95
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	26
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	41.3
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	108102000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	99847000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	85247000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	179700000	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M24D
CY2023	dnli	Share Based Payment Arrangement Vest Or Exercise Of Option Tax Benefit ShareBasedPaymentArrangementVestOrExerciseOfOptionTaxBenefit	0	usd
CY2022	dnli	Share Based Payment Arrangement Vest Or Exercise Of Option Tax Benefit ShareBasedPaymentArrangementVestOrExerciseOfOptionTaxBenefit	0	usd
CY2021	dnli	Share Based Payment Arrangement Vest Or Exercise Of Option Tax Benefit ShareBasedPaymentArrangementVestOrExerciseOfOptionTaxBenefit	0	usd
CY2022	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	usd
CY2023	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	usd
CY2021	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	usd
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	3200000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2800000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	2300000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	7000	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-576000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	30000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	14000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	1000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	30000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	21000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-575000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.273
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.251
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.282
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.145
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.049
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.041
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.032
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.005
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.032
CY2023	dnli	Effective Income Tax Rate Reconciliation Nondeductible Expense Acquisition Related Costs EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionRelatedCosts	-0.035
CY2022	dnli	Effective Income Tax Rate Reconciliation Nondeductible Expense Acquisition Related Costs EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionRelatedCosts	0
CY2021	dnli	Effective Income Tax Rate Reconciliation Nondeductible Expense Acquisition Related Costs EffectiveIncomeTaxRateReconciliationNondeductibleExpenseAcquisitionRelatedCosts	0
CY2023	dnli	Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent	-0.007
CY2022	dnli	Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent	0
CY2021	dnli	Effective Income Tax Rate Reconciliation Nondeductible Expense Compensation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.008
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.004
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.001
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.002
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	89273000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	67492000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	95808000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	69562000	usd
CY2023Q4	dnli	Deferred Tax Assets Research Expense Capitalization DeferredTaxAssetsResearchExpenseCapitalization	119349000	usd
CY2022Q4	dnli	Deferred Tax Assets Research Expense Capitalization DeferredTaxAssetsResearchExpenseCapitalization	61869000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	70824000	usd
CY2023Q4	dnli	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	12663000	usd
CY2022Q4	dnli	Deferred Tax Assets Operating Lease Liability DeferredTaxAssetsOperatingLeaseLiability	14712000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	53226000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	44473000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	17453000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	18381000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	387772000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	347313000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	375795000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	332580000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11977000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	14733000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	5663000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	7314000	usd
CY2023Q4	dnli	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	6314000	usd
CY2022Q4	dnli	Deferred Tax Liabilities Operating Lease Right Of Use Asset DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset	7419000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	43200000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.06
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.60
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.60
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.39
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	19371000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13699000	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	8139000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	168000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	135000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	1042000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	6636000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	5537000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	4725000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	207000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	26175000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	19371000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	13699000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023Q4	us-gaap	Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-145224000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-325991000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-290581000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	137370897	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	125530703	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	121524795	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.06
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.39
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	16500000	shares
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001714899-24-000086-index-headers.html	Edgar Link	pending
0001714899-24-000086-index.html	Edgar Link	pending
0001714899-24-000086.txt	Edgar Link	pending
0001714899-24-000086-xbrl.zip	Edgar Link	pending
dnli-20231231.htm	Edgar Link	pending
dnli-20231231.xsd	Edgar Link	pending
dnli-20231231_g1.jpg	Edgar Link	pending
dnli-20231231_g10.jpg	Edgar Link	pending
dnli-20231231_g11.jpg	Edgar Link	pending
dnli-20231231_g12.jpg	Edgar Link	pending
dnli-20231231_g13.jpg	Edgar Link	pending
dnli-20231231_g14.jpg	Edgar Link	pending
dnli-20231231_g15.jpg	Edgar Link	pending
dnli-20231231_g16.jpg	Edgar Link	pending
dnli-20231231_g17.jpg	Edgar Link	pending
dnli-20231231_g2.jpg	Edgar Link	pending
dnli-20231231_g3.jpg	Edgar Link	pending
dnli-20231231_g4.jpg	Edgar Link	pending
dnli-20231231_g5.jpg	Edgar Link	pending
dnli-20231231_g6.jpg	Edgar Link	pending
dnli-20231231_g7.jpg	Edgar Link	pending
dnli-20231231_g8.jpg	Edgar Link	pending
dnli-20231231_g9.jpg	Edgar Link	pending
exhibit1034compensationrec.htm	Edgar Link	pending
exhibit1035denaliinsiderpo.htm	Edgar Link	pending
exhibit211q42023subsidiari.htm	Edgar Link	pending
exhibit231q42023.htm	Edgar Link	pending
exhibit311q42023.htm	Edgar Link	pending
exhibit312q42023.htm	Edgar Link	pending
exhibit321q42023.htm	Edgar Link	pending
exhibit322q42023.htm	Edgar Link	pending
exhibit44q42023description.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
dnli-20231231_def.xml	Edgar Link	unprocessable
dnli-20231231_lab.xml	Edgar Link	unprocessable
dnli-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
dnli-20231231_htm.xml	Edgar Link	completed
dnli-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DNLI
Denali Therapeutics Inc. Stock $dnli

2024 Q1 Form 10-K Financial Statement

#000171489924000086 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DNLI Denali Therapeutics Inc. Stock $dnli

2024 Q1 Form 10-K Financial Statement

#000171489924000086 Filed on February 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DNLI
Denali Therapeutics Inc. Stock $dnli